First Release of Phase III Head-to-Head Clinical Study Data of Ivonescimab versus Pembrolizumab in NSCLC Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in a Randomized Phase III Clinical Trial in NSCLC HONG KONG, Aug. 11, 2024 /PRNewswire/ –…

ЧЭНДУ, Китай, 12 августа 2024 г. /PRNewswire/ — 10 август компания CATL отметила открытие NING Space, первого в мире нового энергетического центра в Чэнду, провинция Сычуань. Созданный совместно с множеством производителей автомобилей и местными органами власти, NING Space предоставляет…

NEW YORK, Aug. 11, 2024 /PRNewswire/ — Attorney Advertising–Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ: LFCR) and certain of…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.